Search Within

Jose T Baselga

  1. "Elsevier Inc."
Formats
  1. Meeting Abstract (22)
  2. Journal Article (16)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (10)
  2. Solid Tumor Oncology Division (10)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  4. Breast Medicine Service (7)
  5. Survivorship Research (7)
  6. GSK Faculty (6)

More Groups

People
  1. Clifford Hudis (7)
  2. Maurizio Scaltriti (7)
  3. Larry Norton (5)
  4. Andrew Seidman (4)
  5. David Fennelly (4)
  6. George Raptis (4)

More People

Years
  1. 2020 (1)
  2. 2018 (3)
  3. 2017 (2)
  4. 2016 (6)
  5. 2015 (5)
  6. 2014 (6)

More Years

Publications
  1. European Journal of Cancer (25)
  2. Clinical Breast Cancer (4)
  3. Breast (3)
  4. Seminars in Oncology (3)
  5. Pharmacology & Therapeutics (2)
  6. Drug Discovery Today (1)

More Publications

Publishers
  1. Elsevier Inc. (39)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive breast cancer
    Journal Article

    Bines, J.; Procter, M.; Restuccia, E.; Viale, G.; Zardavas, D.; Suter, T.; Arahmani, A.; Van Dooren, V.; Baselga, J.; Clark, E.; more...
    Clinical Breast Cancer (2020)

    Fulltext@MSK | Save
  • Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Journal Article

    Campone, M.; Im, S. A.; Iwata, H.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiełło-Gruszfeld, A.; Pistilli, B.; Tseng, L. M.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
    Meeting Abstract

    Prat, A.; Brase, J. C.; Cheng, Y.; Nuciforo, P.; Paré, L.; Pascual, T.; Martínez, D.; Galván, P.; Vidal, M.; Adamo, B.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
    Journal Article

    Di Cosimo, S.; Campbell, C.; Azim, H. A. Jr; Galli, G.; Bregni, G.; Curigliano, G.; Criscitiello, C.; Izquierdo, M.; de la Pena, L.; Fumagalli, D.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer
    Journal Article

    Baselga, J.; Zamagni, C.; Gómez, P.; Bermejo, B.; Nagai, S. E.; Melichar, B.; Chan, A.; Mángel, L.; Bergh, J.; Costa, F.; more...
    Clinical Breast Cancer (2017)

    Fulltext@MSK | Save
  • Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
    Journal Article

    Loibl, S.; de la Pena, L.; Nekljudova, V.; Zardavas, D.; Michiels, S.; Denkert, C.; Rezai, M.; Bermejo, B.; Untch, M.; Lee, S. C.; more...
    European Journal of Cancer (2017)

    Fulltext@MSK | Save
  • Tumor-specific PI3K inhibition by targeted delivery in head and neck squamous cell carcinoma
    Meeting Abstract

    Mizrachi, A.; Shamay, Y.; Shah, J. K.; Brook, S.; Rajasekhar, V. K.; Humm, J. L.; Baselga, J.; Heller, D. A.; Haimovitz-Friedman, A.; Scaltriti, M.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors
    Meeting Abstract

    Castrovieio-Bermejo, M.; Cruz, C.; Guerra, S.; Llop-Guevara, A.; Gutierrez-Enriquez, S.; Bruna, A.; Rubio, I. T.; Oakin, A.; Nuciforo, P.; Diez, O.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy
    Meeting Abstract

    Scaltriti, M.; Carmona, F. J.; Toska, E.; Cocco, E.; Hyman, D.; Cutler, R.; Avogadri-Connors, F.; Wick, M. J.; Papadopoulos, K. P.; Lalani, A. S.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial
    Journal Article

    Bonner, J. A.; Giralt, J.; Harari, P. M.; Baselga, J.; Spencer, S.; Bell, D.; Raben, D.; Liu, J.; Schulten, J.; Ang, K. K.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save